Akums Drugs and Pharmaceuticals (NSE:AKUMS) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
48 GF Score
Price ₹626.80
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals Research & Development?

Akums Drugs and Pharmaceuticals NSE:AKUMS -1.67% 48 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 48/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Akums Drugs and Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Akums Drugs and Pharmaceuticals Research & Development Related Terms

Akums Drugs and Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals Research & Development Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:AKUMS
48GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Akums Drugs and Pharmaceuticals and its competitors.
Is Akums Drugs and Pharmaceuticals' Research & Development too high?
Akums Drugs and Pharmaceuticals' current Research & Development is ₹0 Mil. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Akums Drugs and Pharmaceuticals' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Akums Drugs and Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
48GF Score

Get the complete analysis for NSE:AKUMS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹626.80
Price